SCHEMBL2066547

SCHEMBL2066547

Cc1cc(S(=O)(=O)c2ccccc2)cnc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HTR6 P50406 1/20 0.47
ALDH1A1 P00352 5/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KMT2A Q03164 2/20 0.43
PKM P14618 2/20 0.43
LMNA P02545 2/20 0.42
PIK3CG P48736 2/20 0.42
PIK3CD O00329 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
FFAR2 O15552 1/20 0.40
MEN1 O00255 1/20 0.40
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30456616 0.77 ALDH1A1 (0.41) HTTALDH1A1MAPTLMNAHSD17B10
SCHEMBL1156197 0.77 ALDH1A1 (0.41) HTTALDH1A1MAPTLMNAHSD17B10
SCHEMBL1641646 0.77 ALDH1A1 (0.41) ALDH1A1MAPTLMNAPIK3CGPIK3CD
SCHEMBL16585960 0.76 POLB (0.59) L3MBTL1ALDH1A1POLBKMT2APKM
SCHEMBL1207411 0.75 ALDH1A1 (0.41) HTTALDH1A1MAPTPKMLMNA
SCHEMBL31028737 0.75 ALDH1A1 (0.41) HTTALDH1A1MAPTPKMLMNA
SCHEMBL11956740 0.73 HTR6 (0.56) HTTL3MBTL1HTR6ALDH1A1MAPT
SCHEMBL16586176 0.72 ALDH1A1 (0.49) HTTALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL1459863 0.72 ALDH1A1 (0.49) ALDH1A1MAPTSMN1; SMN2HSD17B10TDP1
SCHEMBL9900553 0.72 HTR6 (0.61) HTTL3MBTL1HTR6ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101326161-B Novel compounds ASTRAZENECA AB 2013-04-17 CN disclosed
US-8148572-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 US disclosed
US-20090192163-A1 Novel Compounds ASTRAZENECA AB (SE) 2009-07-30 US disclosed
CN-101326161-A Novel compounds ASTRAZENECA AB (SE) 2008-12-17 CN disclosed
EP-1937632-A1 NOVEL COMPOUNDS Astra Zeneca AB (SE) 2008-07-02 EP disclosed
WO-2007039736-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192163-A1 Novel Compounds PAH, PC, DDC HTT 783/4885L3MBTL1 4729/4885HTR6 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.